A. SUBJECT

Botulinum Toxin Injection
- OnabotulinumtoxinA (Botox)
- AbobotulinumtoxinA (Dysport)
- IncobotulinumtoxinA (Xeomin)
- RimabotulinumtoxinB (Myobloc)

B. BACKGROUND

The CareSource Medication Policies are therapy class policies that are used as a guide when determining health care coverage for our members with benefit plans covering prescription drugs. Medication Policies are written on selected prescription drugs requiring prior authorization or Step-Therapy. The Medication Policy is used as a tool to be interpreted in conjunction with the member's specific benefit plan.

The intent of the Botulinum Toxin Injection Program is to encourage appropriate selection of patients for therapy according to product labeling and/or clinical guidelines and/or clinical studies, and also to encourage use of preferred agents.

C. DEFINITIONS

N/A

D. POLICY

CareSource will approve the use of botulinum toxin and consider its use as medically necessary when the following criteria have been met for:

**OnabotulinumtoxinA (Botox) may be indicated for 1 or more of the following:**
- Achalasia, as indicated by **ALL** of the following:
  - Achalasia confirmed by esophageal manometry
  - No response to pharmacologic treatment (eg, long-acting nitrates, calcium channel antagonists)
- Other causes of dysphagia (eg, peptic stricture, carcinoma, lower esophageal ring or extrinsic compression) ruled out by upper gastrointestinal endoscopy
- Patient not candidate for pneumatic dilation or surgical myotomy
- Progressive dysphagia for liquids and solids

**Anal fissure,** as indicated by **ALL** of the following:
- At least 2 months of symptoms, including **1 or more** of the following:
  - Nocturnal pain and bleeding
  - Post-defecation pain
- Failure of or intolerance to topical nitrates
- No anal fistula
- No hemorrhoids
- No HIV disease
- No inflammatory bowel disease
- No perianal abscess
- No perianal cancer
- No previous perianal surgery
- Patient not surgical candidate or has refused surgery

**Blepharospasm,** as indicated by **ALL** of the following:
- Benign essential blepharospasm
- Blepharospasm associated with dystonia
- Blepharospasm associated with facial nerve (cranial nerve VII) disorders such as Bell palsy
- No neuromuscular disease (eg, myasthenia gravis)

**Cervical dystonia (spasmodic torticollis),** as indicated by **ALL** of the following:
- Cervical dystonia (spasmodic torticollis)
- Neck pain or abnormal head position causing adverse effect on daily functioning
- No fixed contractures causing decreased neck range of motion
- No infection at proposed injection site
- No neuromuscular disease (eg, myasthenia gravis)
- No prior surgical treatment

**Gustatory sweating (Frey syndrome, auriculotemporal syndrome)** when condition is complication of parotidectomy

**Hemi Facial Spasm**

**Hyperhidrosis,** as indicated by **ALL** of the following:
*(Excluded for Marketplace members (OH, KY, & IN JUST4ME)*
- Axillary hyperhidrosis, with resting sweat production of 50 mg per axilla measured over 5 minutes at room temperature
- Failed conservative treatment using topical agents
- Secondary causes of hyperhidrosis (eg, hyperthyroidism) have been evaluated and, if necessary, treated.
- Significant effect of hyperhidrosis upon daily activities

**Laryngeal dystonia (ie, hoarseness),** as indicated by **ALL** of the following:
- Adductor-type spasmodic dysphonia confirmed by fiber optic laryngoscopy
- Moderate to severe difficulty in phonation

**Migraine headache prophylaxis** needed, as indicated by **ALL** of the following:
- Migraine headache, as indicated by 5 or more attacks with **ALL** of the following:
  - Headache symptoms, as indicated by **2 or more** of the following:
    - Aggravation by or causing avoidance of routine physical activity
Moderate or severe pain intensity
- Pulsating quality
- Unilateral location
  - Migraine associated symptoms, as indicated by 1 or more of the following:
    - Nausea or vomiting
    - Photophobia and phonophobia
- Migraine headache frequency occurring 15 or more days per month
- No medication-overuse headaches
- No neuromuscular disease (eg, myasthenia gravis)
- Other therapeutic options have been ineffective or not tolerated for trial of at least 3 months, as indicated by 1 or more of the following:
  - Use of ergotamine, triptans, or combination analgesics for 10 or more days per month
  - Use of simple analgesics or any combination of ergotamine, triptans, analgesics, and opioids for 15 or more days per month

Motor tics, as indicated by ALL of the following:
- Failure to respond to trials of several different neuroleptic drugs (eg, haloperidol)
- Patient unable to adequately suppress tics
- Tics causing interference with daily functioning

Neurogenic urinary incontinence, neurogenic detrusor over activity, or detrusor sphincter dyssynergia, as indicated by ALL of the following:
- Condition secondary to spinal cord injury or neurologic disease, including but not limited to multiple sclerosis
- No acute urinary tract infection
- No acute urinary retention unless patient receiving regular clean intermittent catheterization
- Surgical treatment or balloon sphincter dilatation is not indicated, has been refused, or has failed.
- Unresponsive or intolerant to pharmacologic therapy including anticholinergic medication
  - Overactive bladder with urge urinary incontinence, as indicated by ALL of the following:
    - Failure of or intolerance to anticholinergic medication
    - No acute urinary retention
    - No acute urinary tract infection
    - Urge urinary incontinence demonstrated on urodynamic testing

Sialorrhea (excessive salivation)

Spasticity, as indicated by 1 or more of the following:
- Child with cerebral palsy receiving rehabilitation
- Upper extremity spasticity in adult due to stroke

Strabismus, as indicated by ALL of the following:
- Deviation of 50 prism diopters or less
- Strabismus not due primarily to Duane syndrome with lateral rectus weakness
- Strabismus not due primarily to restrictive strabismus
- Strabismus not due primarily to secondary strabismus caused by prior surgical over-recession of antagonist muscle

Upper extremity focal dystonia (eg, writer's cramp), as indicated by ALL of the following:
- Extremity pain or abnormal hand or forearm position causing adverse effect on daily functioning
- No prior surgical treatment

**AbobotulinumtoxinA (Dysport)** may be indicated for **1 or more** of the following:

**Blepharospasm**, as indicated by **ALL** of the following:
- Diagnosis of benign essential blepharospasm

**Cervical dystonia (spasmodic torticollis)**, as indicated by **ALL** of the following:
- Neck pain or abnormal head position causing adverse effect on daily functioning
- No fixed contractures causing decreased neck range of motion
- No prior surgical treatment

**Hemi facial spasm**

**Hyperhidrosis**, as indicated by **ALL** of the following:

(Excluded for Marketplace members (OH, KY, & IN JUST4ME)
- Axillary hyperhidrosis, with resting sweat production of 50 mg per axilla measured over 5 minutes at room temperature
- Failed conservative treatment using topical agents
- Secondary causes of hyperhidrosis (eg, hyperthyroidism) have been evaluated and, if necessary, treated.
- Significant effect of hyperhidrosis upon daily activities

**Sialorrhea (excessive salivation)**

**Spasticity**, as indicated by **1 or more** of the following:
- Child with cerebral palsy receiving rehabilitation
- Upper extremity spasticity in adult due to stroke

**Upper extremity dystonia (eg, writer's cramp)**, as indicated by **ALL** of the following:
- Extremity pain or abnormal hand or forearm position causing adverse effect on daily functioning
- No prior surgical treatment

**RimabotulinumtoxinB (Myobloc)** may be indicated when **1 or more** of the following are present:

**Cervical dystonia (spasmodic torticollis)** and **ALL** of the following:
- Age 16 years or older
- Neck pain or abnormal head position causing adverse effect on daily functioning
- No fixed contractures causing decreased neck range of motion
- No infection at proposed injection site
- No neuromuscular disease (eg, myasthenia gravis)

**Sialorrhea (excessive salivation)** due to neurologic disease

**IncobotulinumtoxinA (Xeomin)** may be indicated when **1 or more** of the following are present:

**Cervical dystonia (spasmodic torticollis)** and **ALL** of the following:
- Neck pain or abnormal head position causing adverse effect on daily functioning
- No fixed contractures causing decreased neck range of motion
- No neuromuscular disease (eg, myasthenia gravis)

**Blepharospasm**, as indicated by **ALL** of the following:
- No neuromuscular disease (eg, myasthenia gravis)
- Blepharospasm, as indicated by **1 or more** of the following:
  - Benign essential blepharospasm
  - Blepharospasm associated with dystonia
  - Blepharospasm associated with facial nerve (cranial nerve VII) disorders such as Bell palsy
  - Prior treatment failure with onabotulinumtoxinA (Botox)
NOTE: Documented diagnosis must be confirmed by portions of the individual's medical record which will confirm the presence of disease and will need to be supplied with prior authorization request. These medical records may include, but not limited to test reports, chart notes from provider's office or hospital admission notes.

For Medicare Plan members, reference the below link to search for Applicable National Coverage Descriptions (NCD) and Local Coverage Descriptions (LCD):

If there is no NCD or LCD present, reference the CareSource Policy for coverage.

Conditions of Coverage

**HCPCS**
- J0585 OnabotulinumtoxinA (Botox)
- J0586 AbobotulinumtoxinA (Dysport)
- J0587 RimabotulinumtoxinB (Myobloc)
- J0588 IncobotulinumtoxinA (Xeomin)

**CPT**

**Place of Service**
- Office, Outpatient
  - **Preferred place of service is in the office or outpatient setting.**

**Note:** CareSource supports administering injectable medications in various settings, as long as those services are furnished in the most appropriate and cost effective setting that are supportive of the patient’s medical condition and unique needs and condition. The decision on the most appropriate setting for administration is based on the member’s current medical condition and any required monitoring or additional services that may coincide with the delivery of the specific medication.

**Authorization Period**
Approved initial authorizations are valid for 6 months. Continued treatment may be considered when the member has shown biological response to treatment. **ALL** authorizations are subject to continued eligibility.

E. REVIEW/REVISION HISTORY

<table>
<thead>
<tr>
<th>Date Issued:</th>
<th>06/15/2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date Reviewed:</td>
<td>06/15/2011, 02/20/2013, 12/31/2014</td>
</tr>
<tr>
<td>Date Revised:</td>
<td>02/20/2013 – Removed approvable off-label indications and safety section, beta blockers and CCB’s removed from prophylactic treatment of chronic migraine, added overactive bladder to Botox indications, added Neurologist to Blepharospasm.</td>
</tr>
<tr>
<td></td>
<td>12/31/2014 – Revision to clarify exclusions.</td>
</tr>
</tbody>
</table>

F. REFERENCES


The medical Policy Statement detailed above has received due consideration as defined in the Medical Policy Statement Policy and is approved.

Independent medical review – April 2013